DEXCOM, INC. (DXCM) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $29.7M (period ending 2009-12-31) to $4.66B (period ending 2025-12-31) — a 37.2% annual pace across 16 year(s) of filed history.
- Net margin turned from a loss (-180.3%) to a 17.9% margin over that same span.
- Across 49 tracked quarters, the strongest was $1.31B (quarter ending 2026-06-30) and the weakest was $11.7M (quarter ending 2010-09-30).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $4.66B | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Gross profit | $2.80B | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Operating income | $911.8M | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Net income | $836.3M | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Diluted EPS | $2.09 | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Total assets | $6.34B | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Total liabilities | $3.59B | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Cash & equivalents | $917.7M | 2025-12-31 | 10-K | 0001093557-26-000027 |
| Operating cash flow | $1.44B | 2025-12-31 | 10-K | 0001093557-26-000027 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $1.31B | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Gross profit | $830.0M | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Operating income | $318.3M | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Net income | $249.1M | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Diluted EPS | $0.64 | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Total assets | $6.46B | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Total liabilities | $3.83B | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Cash & equivalents | $1.10B | 2026-06-30 | 10-Q | 0001093557-26-000143 |
| Operating cash flow | $525.6M | 2026-03-31 | 10-Q | 0001093557-26-000073 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Dexcom, Inc. (DXCM) operates in the medical devices sector, with a scale evident from its substantial revenue of $4.66 billion for the year ending December 31, 2025. This figure represents a remarkable transformation from a mere $29.7 million in 2009, reflecting an impressive annual growth rate of 37.2% over 16 years. The company’s revenue trajectory showcases a robust expansion, transitioning from losses to substantial net income of $836.3 million in the latest period.
Dexcom’s gross profit has mirrored this upward trend, rising from $48.6 million in 2010 to $2.80 billion in 2025, indicating efficient cost management and product pricing strategies. Operating income has also surged, from negative figures in the early years to $911.8 million in 2025, underscoring improved operational efficiency. The company’s net margin, once a steep loss of 180.3%, has reversed to a healthy 17.9% margin, signaling profitability and financial stability.
In examining the quarterly data, Dexcom’s revenue reached its peak at $1.31 billion in Q2 2026, while the lowest was $11.7 million in Q3 2010, highlighting seasonal fluctuations and market dynamics. Investors should monitor the company’s ability to sustain this growth trajectory, particularly its capacity to manage increasing competition and regulatory pressures within the medical devices industry. Additionally, tracking operating cash flow trends will be crucial, as it reflects the company’s financial health and capacity for future investments and expansion.
Source: SEC EDGAR company facts for CIK 0001093557 · filings index